Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

BioLight forms strategic partnership with Rock-One to expand its presence within China

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today an agreement to enter into a strategic partnership with Rock-One International Holdings Ltd., a holding company specializing in investment activities, including in the high tech and biomedical industries.

2 Apr 2015

University of York student helps develop new drug release gel

A Chemistry undergraduate at the University of York has helped to develop a new drug release gel, which may help avoid some of the side effects of painkillers such as ibuprofen and naproxen.

1 Apr 2015

Biomedical researchers successfully convert microbubble technology into nanoparticles

Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumours to potentially deliver targeted, therapeutic payloads.

31 Mar 2015

Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

Columbia Laboratories, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring.

30 Mar 2015

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.

30 Mar 2015

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed.

30 Mar 2015

MTI Expo 2015 to focus on engineering requirements in the medical technology sector

April 29-30, Ricoh Stadium, Coventry sees the next edition of the Med-Tech Innovation exhibition take place – engineering is the thread that runs through the whole show.

30 Mar 2015

New targeted therapy promises to reduce frequency and intensity of breakouts

Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples.

23 Mar 2015

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Late stage pancreatic cancer benefits from photodynamic therapy (PDT) but the resources needed for the usual accompanying dosimetry present barriers, Dartmouth researchers Jonathan T. Elliott, PhD and Brian C. Pogue, PhD have mitigated by using common clinical technologies.

23 Mar 2015

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO).

23 Mar 2015

Sandia biosciences technologies could soon find their way into doctors' offices

Technologies developed in Sandia National Laboratories' biosciences program could soon find their way into doctors' offices -- devices like wearable microneedles that continuously analyze electrolyte levels and a lab-on-a-disk that can test a drop of blood for 64 different diseases in minutes.

20 Mar 2015

MTfp-siRNA reduces blood vessel infarct, improves overall brain activity in ischemic stroke model

BIOASIS TECHNOLOGIES INC., a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-‐brain barrier (BBB), announces the results from an animal ischemic stroke model performed at the National Research Council Canada with the biOasis Transcend carrier peptide, MTfp and siRNA (MTfp-‐siRNA).

19 Mar 2015

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

Pharmalink AB, a specialty pharma company, announces that it has acquired a novel product candidate in development for treating inflammation from Synartro AB. No financial details are disclosed.

18 Mar 2015

BD announces completion of CareFusion acquisition

Becton, Dickinson and Company today announced that it completed its acquisition of CareFusion Corporation pursuant to the terms of its previously announced Agreement and Plan of Merger, dated October 5, 2014 (the "Merger Agreement").

From BD (Becton, Dickinson and Company) 17 Mar 2015

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise.

17 Mar 2015

Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Inc., a biopharmaceutical company, and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company, announced today that on March 13, 2015, they have entered into a definitive merger agreement.

16 Mar 2015

Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Treating respiratory disease is often difficult because drugs have to cross biological barriers such as respiratory tissue and mucosa, and must therefore be given in large quantities in order for an effective amount to reach the target.

13 Mar 2015

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families.

12 Mar 2015

InMed, University of Debrecen partner to develop novel therapies to treat ocular allergies

InMed Pharmaceuticals Inc. announces it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms.

10 Mar 2015

Impax Laboratories acquires Tower Holdings and Lineage Therapeutics

Impax Laboratories, Inc. today announced that it has completed its acquisition of Tower Holdings, Inc. (including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC), and Lineage Therapeutics Inc. (together, the "Companies").

10 Mar 2015

Drug Delivery News and Research

Further Reading

BioLight forms strategic partnership with Rock-One to expand its presence within China

University of York student helps develop new drug release gel

Biomedical researchers successfully convert microbubble technology into nanoparticles

Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

Clonidine Topical Gel fails to meet primary endpoint in Phase 3 study for treatment of painful diabetic neuropathy

MTI Expo 2015 to focus on engineering requirements in the medical technology sector

New targeted therapy promises to reduce frequency and intensity of breakouts

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Sandia biosciences technologies could soon find their way into doctors' offices

MTfp-siRNA reduces blood vessel infarct, improves overall brain activity in ischemic stroke model

Pharmalink AB acquires anti-inflammatory drug candidate from Synartro AB

BD announces completion of CareFusion acquisition

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Ruthigen, Pulmatrix sign definitive merger agreement

Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

InMed, University of Debrecen partner to develop novel therapies to treat ocular allergies

Impax Laboratories acquires Tower Holdings and Lineage Therapeutics

Event guide: World ADC San Diego eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo